Pharmacological therapy for the prevention and treatment of weakness after critical illness: A systematic review

Critical Care Medicine

Volumn 44, Issue 6, 2016, Pages 1198-1205

  Shepherd, Stephen J ^a   Newman, Richard ^b   Brett, Stephen J ^c   Griffith, David M ^d  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

critical illness; muscular diseases; polyneuropathy

Indexed keywords

GLUTAMINE; GROWTH HORMONE; IMMUNOGLOBULIN; OXANDROLONE; PROPRANOLOL; ANABOLIC AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IMMUNOLOGIC FACTOR; INSULIN;

CRITICAL ILLNESS; HUMAN; INTENSIVE CARE UNIT; META ANALYSIS; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PHYSICAL PERFORMANCE; POLYNEUROPATHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; COMPLICATION; HYPERGLYCEMIA; POLYNEUROPATHIES;

ADRENERGIC BETA-ANTAGONISTS; ANABOLIC AGENTS; CRITICAL ILLNESS; GLUTAMINE; GROWTH HORMONE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INSULIN; MUSCLE WEAKNESS; OXANDROLONE; POLYNEUROPATHIES; PROPRANOLOL;

EID: 84960154798     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001652     Document Type: Review

References (66)

1. Herridge MS Tansey CM Matte A Functional disability 5 years after acute respiratory distress syndrome. New Engl J Med 2011 364 1293 1304
2. Stevens RD Marshall SA Cornblath DR A framework for diagnosing and classifying intensive care unit-Acquired weakness. Crit Care Med 2009 37 S299 S308
3. Kress JP Hall JB ICU-Acquired weakness and recovery from critical illness. N Engl J Med 2014 371 287 288
4. Latronico N Bolton CF Critical illness polyneuropathy and myopathy: A major cause of muscle weakness and paralysis. Lancet Neurol 2011 10 931 941
5. Hadley JS Hinds CJ Anabolic strategies in critical illness. Curr Opin Pharmacol 2002 2 700 707
6. Derde S Hermans G Derese I Muscle atrophy and preferential loss of myosin in prolonged critically ill patients. Crit Care Med 2012 40 79 89
7. Latronico N Neuromuscular alterations in the critically ill patient: Critical illness myopathy, critical illness neuropathy, or both? Intensive Care Med 2003 29 1411 1413
8. Hermans G De Jonghe B Bruyninckx F Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Re 2009 1 CD006832
9. Welch V Petticrew M Tugwell P PRISMA-Equity Bellagio Group PRISMA-Equity 2012 extension: Reporting guidelines for systematic reviews with a focus on health equity. PLoS Med 2012 9 e1001333
10. Takala J Ruokonen E Webster NR Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999 341 785 792
11. Higgins JPT Green S The Cochrane Collaboration, 2011. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available at: http://www.cochrane-handbook.org. Accessed March 3, 2016
12. Guyatt GH Oxman AD Vist GE GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008 336 924 926
13. Demling RH DeSanti L Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid. Burns 2003 29 793 797
14. Callahan LA Supinski GS Hyperglycemia and acquired weakness in critically ill patients: Potential mechanisms. Crit Care 2009 13 125
15. Dimitriadis G Mitrou P Lambadiari V Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract 2011 93 Suppl 1 S52 S59
16. Biolo G De Cicco M Lorenzon S Treating hyperglycemia improves skeletal muscle protein metabolism in cancer patients after major surgery. Crit Care Med 2008 36 1768 1775
17. Mikaeili H Yazdchi M Barazandeh F Euglycemic state reduces the incidence of critical illness polyneuropathy and duration of ventilator dependency in medical intensive care unit. Bratisl Lek Listy 2012 113 616 619
18. Pichard C Kyle U Chevrolet JC Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: A prospective, randomized, controlled study. Crit Care Med 1996 24 403 413
19. Gamrin L Essén P Hultman E Protein-sparing effect in skeletal muscle of growth hormone treatment in critically ill patients. Ann Surg 2000 231 577 586
20. Norbury W Propranolol attenuates factors affecting hypermetabolism in pediatric burn patients. Critical Care 2007 London, England P152. (abstract number)
21. Herndon DN Hart DW Wolf SE Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 2001 345 1223 1229
22. Mohr M Englisch L Roth A Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997 23 1144 1149
23. Brunner R Rinner W Kitzberger R Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: A prospective, randomized, placebo-controlled, double-blinded trial. Crit Care 2013 17 R213
24. Bollhalder L Pfeil AM Tomonaga Y A systematic literature review and meta-Analysis of randomized clinical trials of parenteral glutamine supplementation. Clin Nutr 2013 32 213 223
25. van Zanten AR Glutamine and antioxidants: Status of their use in critical illness. Current Opin Clin Nutr Metab Care 2015 18 179 186
26. Tjäder I Rooyackers O Forsberg AM Effects on skeletal muscle of intravenous glutamine supplementation to ICU patients. Intensive Care Med 2004 30 266 275
27. Sakurai Y Aarsland A Herndon DN Stimulation of muscle protein synthesis by long-Term insulin infusion in severely burned patients. Ann Surg 1995 222 283 294; 294-297
28. Debroy MA Wolf SE Zhang XJ Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. J Trauma 1999 47 904 910
29. Ferrando AA Chinkes DL Wolf SE A submaximal dose of insulin promotes net skeletal muscle protein synthesis in patients with severe burns. Ann Surg 1999 229 11 18
30. Hart DW Herndon DN Klein G Attenuation of posttraumatic muscle catabolism and osteopenia by long-Term growth hormone therapy. Ann Surg 2001 233 827 834
31. Hart DW Wolf SE Ramzy PI Anabolic effects of oxandrolone after severe burn. Ann Surg 2001 4 556 564
32. Demling RH DeSanti L Restoration of body weight, function, and wound healing after severe burns using the anabolic agent oxandrolone is not age dependent. Ostomy Wound Manage 2002 48 42 47
33. Hart DW Wolf SE Chinkes DL Beta-blockade and growth hormone after burn. Ann Surg 2002 236 450 456
34. Suman OE Thomas SJ Wilkins JP Effect of exogenous growth hormone and exercise on lean mass and muscle function in children with burns. J Appl Physiol (1985) 2003 94 2273 2281
35. Wolf SE Thomas SJ Dasu MR Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. Ann Surg 2003 237 801 810
36. Gore DC Herndon DN Wolfe RR Comparison of peripheral metabolic effects of insulin and metformin following severe burn injury. J Trauma 2005 2 316 323. discussion 322-323
37. Van den Berghe G Schoonheydt K Becx P Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005 64 1348 1353
38. Przkora R Herndon DN Suman OE Beneficial effects of extended growth hormone treatment after hospital discharge in pediatric burn patients. Ann Surg 2006 243 796 801
39. Hermans G Wilmer A Meersseman W Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med 2007 175 480 489
40. Przkora R Herndon DN Suman OE The effects of oxandrolone and exercise on muscle mass and function in children with severe burns. Pediatrics 2007 119 e109 e116
41. Branski LK Herndon DN Barrow RE Randomized controlled trial to determine the efficacy of long-Term growth hormone treatment in severely burned children. Ann Surg 2009 250 514 523
42. Hermans G Schrooten M Van Damme P Benefits of intensive insulin therapy on neuromuscular complications in routine daily critical care practice: A retrospective study. Crit Care 2009 13 R5
43. Tuvdendorj D Chinkes DL Zhang XJ Long-Term oxandrolone treatment increases muscle protein net deposition via improving amino acid utilization in pediatric patients 6 months after burn injury. Surgery 2011 149 645 653
44. Porro LJ Herndon DN Rodriguez NA Five-year outcomes after oxandrolone administration in severely burned children: A randomized clinical trial of safety and efficacy. J Am Coll Surg 2012 214 489 502
45. Hermans G Wilmer A Meersseman W Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med 2007 175 480 489
46. van den Berghe G Wouters P Weekers F Intensive insulin therapy in critically ill patients. N Engl J Med 2001 345 1359 1367
47. Van den Berghe G Wilmer A Hermans G Intensive insulin therapy in the medical ICU. N Engl J Med 2006 354 449 461
48. Finfer S Chittock DR Su SY NICE-SUGAR Study Investigators Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009 360 1283 1297
49. Finfer S Liu B Chittock DR NICE-SUGAR Study Investigators Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012 367 1108 1118
50. Wernerman J Desaive T Finfer S Continuous glucose control in the ICU: Report of a 2013 round table meeting. Crit Care 2014 18 226
51. Gervasio JM Dickerson RN Swearingen J Oxandrolone in trauma patients. Pharmacotherapy 2000 20 1328 1334
52. Bulger EM Jurkovich GJ Farver CL Oxandrolone does not improve outcome of ventilator dependent surgical patients. Ann Surg 2004 240 472 478
53. De Letter MA van Doorn PA Savelkoul HF Critical illness polyneuropathy and myopathy (CIPNM): Evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol 2000 106 206 213
54. Bolton CF Neuromuscular manifestations of critical illness. Muscle Nerve 2005 32 140 163
55. Berry SD Ngo L Samelson EJ Competing risk of death: An important consideration in studies of older adults. J Am Geriatr Soc 2010 58 783 787
56. Wolbers M Koller MT Stel VS Competing risks analyses: Objectives and approaches. Eur Heart J 2014 35 2936 2941
57. Putter H Fiocco M Geskus RB Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 2007 26 2389 2430
58. Hinds CJ Administration of growth hormone to catabolic patients. Growth Horm IGF Res 1999 9 Suppl A 71 75
59. Ferrando AA Sheffield-Moore M Yeckel CW Testosterone administration to older men improves muscle function: Molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002 282 E601 E607
60. Latham NK Anderson CS Reid IR Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: A systematic review. J Am Geriatr Soc 2003 51 1219 1226
61. Malafarina V Uriz-Otano F Iniesta R Sarcopenia in the elderly: Diagnosis, physiopathology and treatment. Maturitas 2012 71 109 114
62. Wagner KR Muscle regeneration through myostatin inhibition. Curr Opin Rheumatol 2005 17 720 724
63. Bo Li Z Zhang J Wagner KR Inhibition of myostatin reverses muscle fibrosis through apoptosis. J Cell Sci 2012 125 3957 3965
64. Lee SJ McPherron AC Myostatin and the control of skeletal muscle mass. Curr Opin Genet Dev 1999 9 604 607
65. Schuelke M Wagner KR Stolz LE Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004 350 2682 2688
66. Berardi E Annibali D Cassano M Molecular and cell-based therapies for muscle degenerations: A road under construction. Front Physiol 2014 5 119